Method of enhancing the therapeutic efficacy of fexapotide triflutate in treating LUTS
Disclosed are methods of enhancing the therapeutic efficacy of Fexapotide Triflutate (TF) in treating LUTS, both irritative and obstructive, that include administering a composition comprising FT at least twice over a period spanning more than one year. The methods are capable of providing an enhanced therapeutic effect in treating nocturia, and in improving urinary flow, when compared to the therapeutic effect achieved by administration of the same or twice the total amount of FT administered.
1. A method of enhancing the therapeutic efficacy of Fexapotide Triflutate (FT) in improving at least the urinary peak flow rate (Qmax) mean change from baseline and/or the urinary flow worsening/obstruction as measured by the inability to provide a urine volume>125 ml, comprising
a) identifying and selecting patients having irritative or obstructive Lower Urinary Tract Symptoms (LUTS) LUTS;
b) first administering a composition comprising FT to a patient identified and selected in (a) above; and
c) subsequently administering a composition comprising FT to the patient at least more than one year after the first administration, thereby administering a total dosage of FT comprising the sum of the first and subsequent administrations of FT,
wherein the method improves at least the urinary peak flow rate (Qmax) mean change from baseline and/or the urinary flow worsening/obstruction as measured by the inability to provide a urine volume>125 ml, in an amount greater than the respective improvement in patients that were administered the same total dosage of FT or twice the total dosage of FT in a single administration.
2. The method of claim 1 , wherein the method comprises administration of Fexapotide Triflutate and a carrier.
3. The method of claim 1 , wherein the method comprises administration of Fexapotide Triflutate in a concentration of 2.5 mg/L.
4. The method of claim 1 , wherein Fexapotide Triflutate is administered by a method selected from the group consisting of orally, subcutaneously, intradermally, intranasally, intravenously, intramuscularly, intrathecally, intranasally, intratumorally, topically, transrectally, transperitoneally, and transdermally.
5. A method of enhancing the therapeutic efficacy of Fexapotide Triflutate (FT) in improving at least nocturia in patients having Lower Urinary Tract Symptoms (LUTS), comprising:
a) identifying and selecting patients having irritative symptoms of LUTS;
b) administering a first composition comprising Fexapotide Triflutate (FT) to a patient identified and selected in (a) above; and
c) administering a second composition comprising FT to the patient at least more than one year after administering the first composition, thereby administering a total dosage of FT comprising the sum of the first and subsequent administrations of FT,
wherein the method improves at least nocturia in an amount greater than the improvement in nocturia in patients that were administered the same total dosage of FT in a single administration.
6. The method of claim 5 , wherein FT is present in the first composition in a concentration of about 2.5 mg/l.
7. The method of claim 6 , wherein FT is present in the second composition in a concentration of about 2.5 mg/l.
8. A method of enhancing the therapeutic efficacy of Fexapotide Triflutate (FT) in treating obstructive symptoms of patients with Lower Urinary Tract Symptoms (LUTS), comprising:
a) identifying and selecting patients having obstructive symptoms of LUTS;
b) administering a first composition comprising Fexapotide Triflutate (FT) to a patient identified and selected in (a) above; and
c) administering a second composition comprising FT to the patient at least more than one year after administering the first composition, thereby administering a total dosage of FT comprising the sum of the first and subsequent administrations of FT,
wherein the method improves at least one obstructive symptom of LUTS in an amount greater than the respective improvement in patients that were administered the same total dosage of FT or twice the total dosage of FT in a single administration.
9. The method of claim 8 , wherein the obstructive symptoms are selected from the group consisting of straining, weak stream, intermittent stream, and incomplete emptying.
10. The method of claim 8 , wherein FT is present in the first composition in a concentration of about 2.5 mg/l.
11. The method of claim 10 , wherein FT is present in the second composition in a concentration of about 2.5 mg/l.
12. The method of claim 8 , wherein the method provides an improvement in peak flow rate (Qmax) mean change from baseline of from about 100% to about 200%, when compared to a placebo control.
13. The method of claim 8 , wherein the method provides an improvement in peak flow rate (Qmax) mean change from baseline, of from about 95% to about 105%, when compared to administration of the same total amount of FT only once.
14. The method of claim 1 , wherein the method provides an improvement in peak flow rate (Qmax) mean change from baseline, of from about 95% to about 105%, when compared to administration of the same total amount of FT only once.